tbuckley/cabot-search huggingface dataset:
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology
Authors: Katrin P. Guillen, Maihi Fujita, Andrew J. Butterfield, Sandra D. Scherer, Matthew H. Bailey, Zhengtao Chu, Yoko S. DeRose, Ling Zhao, Emilio Cortes-Sanchez, Chieh-Hsiang Yang, Jennifer Toner, Guoying Wang, Yi Qiao, Xiaomeng Huang, Jeffery A. Greenland, Jeffery M. Vahrenkamp, David H. Lum, Rachel E. Factor, Edward W. Nelson, Cindy B. Matsen, Jane M. Poretta, Regina Rosenthal, Anna C. Beck, Saundra S. Buys, Christos Vaklavas, John H. Ward, Randy L. Jensen, Kevin B. Jones, Zheqi Li, Steffi Oesterreich, Lacey E. Dobrolecki, Satya S. Pathi, Xing Yi Woo, Kristofer C. Berrett, Mark E. Wadsworth, Jeffrey H. Chuang, Michael T. Lewis, Gabor T. Marth, Jason Gertz, Katherine E. Varley, Bryan E. Welm, Alana L. Welm
Journal: Nature Cancer (2022)

Models that recapitulate the complexity of human tumors are urgently needed to develop more effective cancer therapies. We report a bank of human patient-derived xenografts (PDXs) and matched organoid cultures from tumors that represent the greatest unmet need: endocrine-resistant, treatment-refractory and metastatic breast cancers. We leverage matched PDXs and PDX-derived organoids (PDxO) for drug screening that is feasible and cost-effective with in vivo validation. Moreover, we demonstrate the feasibility of using these models for precision oncology in real time with clinical care in a case of triple-negative breast cancer (TNBC) with early metastatic recurrence. Our results uncovered a Food and Drug Administration (FDA)-approved drug with high efficacy against the models. Treatment with this therapy resulted in a complete response for the individual and a progression-free survival (PFS) period more than three times longer than their previous therapies. This work provides valuable methods and resources for functional precision medicine and drug development for human breast cancer.
Oncology
Authors: J. E. Karp
Journal: JAMA (1992)

Molecular oncology continues to unravel the fundamental interplay among normally occurring, growth-promoting genes (oncogenes), tumor suppressor genes, and cell cycle regulators that determines the balance between cellular growth and differentiation. Mechanisms that perturb this balance can result in malignant transformation and increasingly serve as molecular targets for manipulation. Recent innovations in molecular technology provide an increasingly sensitive dissection of the normal mechanisms by which tumor suppressor genes modulate cell growth. For example, the protein product of the tumor suppressor gene p53 (located on the short arm of chromosome 17, 17p13) may exert its net growth inhibitory activity by binding to (and altering the function of) specific sequences of DNA.<sup>1,2</sup>In response to certain types of DNA damage (eg, UV light), the p53 protein is upregulated, prolonging the G1 phase of the cell cycle and allowing the cell time to repair DNA breaks.<sup>3</sup>Cells with aberrant net p53 expression
Highlights
Journal: JAMA Psychiatry (2019)

Estradiol for Schizophrenia Among Women of Childbearing Age 1009Estradiol is reported to have antipsychotic properties, but this has not been independently replicated.Weiser and colleagues conducted a single-site 8-week randomized placebocontrolled trial of 200 μg of estradiol in a patch in 100 women of childbearing age and found that the estradiol patch led to significantly greater improvement in the primary outcome than placebo, with the strongest effect in older women.These results replicate the finding that estradiol is antipsychotic in women of childbearing age and they have implications for new therapeutic approaches.
Refractory folliculitis decalvans treated with adalimumab: A case series of 23 patients
Authors: Matilde Iorizzo, Michela Starace, Sergio Vano-Galvan, Bianca Maria Piraccini, Pascal Reygagne, Lidia Rudnicka, Tatiana Silyuk, Rodney Sinclair, Antonella Tosti
Journal: Journal of the American Academy of Dermatology (2022)
Implementation of an Antibiotic Stewardship Program in Long-term Care Facilities Across the US
Authors: Morgan J. Katz, Pranita D. Tamma, Sara E. Cosgrove, Melissa A. Miller, Prashila Dullabh, Therese A. Rowe, Roy Ahn, Kathleen Speck, Yue Gao, Savyasachi Shah, Robin L. P. Jump
Journal: JAMA Network Open (2022)

Antibiotic overuse in long-term care (LTC) is common, prompting calls for antibiotic stewardship programs (ASPs) designed for specific use in these settings. The optimal approach to establish robust, sustainable ASPs in LTC facilities is unknown.
Encyclopedia
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
WOMEN'S CLUBS AND PATENT MEDICINE.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Action of Light as a Therapeutic Agent. By Leonard K. Hirshberg, Baltimore, Md. Fiske Fund Prize Dissertation. Cloth. Pp. 49. Providence: Snow &amp;amp; Farnham. 1904. Roentgen-Ray Diagnosis and Therapy. By Carl Beck, M.D., Professor of Surgery in the New York Postgraduate Medical School and Hospital. With 322 illustrations In the text. Cloth. Pp. 460. Price, $4.00. New York and London: D. Appleton &amp;amp; Co. 1904. Light Energy; Its Physics, Physiological Action and Therapeutic …
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Amenorrhea Evaluation and Management
Authors: Yue Zhang, Yizhou Huang, Jianhong Zhou
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pathology
Authors: Kenneth M. Brinkhous
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New generation psychological treatments in chronic pain
Authors: Lance M McCracken, Lin Yu, Kevin E Vowles
Journal: BMJ (2022)

Abstract Chronic pain conditions are common and have a considerable impact on health and wellbeing. This impact can be reduced by cognitive behavioral therapy (CBT), the most commonly applied psychological approach to chronic pain. At the same time, CBT continues to develop, and now includes what is sometimes called “third wave” CBT. In this review, we examine the evidence for application of acceptance and commitment therapy (ACT), a principal example of this new wave or latest generation of treatment approaches, in people with chronic pain. We identified 25 randomized controlled trials of ACT for adults with chronic pain. Across the included trials, small to large effect sizes favoring ACT were reported for key outcomes including pain interference, disability, depression, and quality of life. Evidence from three studies provided some support for the cost effectiveness of ACT for chronic pain. Evidence also supported the mediating role of theoretically consistent processes of change (psychological flexibility) in relation to treatment outcomes. Investigation of moderators and predictors of outcomes was limited and inconsistent. In future, a greater focus on process based treatments is recommended. This should include continued identification of evidence based processes of change, and research methods more suited to understanding the experience and needs of individual people.
Inhaled budesonide may be less potent than beclomethasone in primary care
Journal: BMJ (1998)

Multiple doses of anticholinergics are beneficial in severe, acute childhood asthmaThe addition of anticholinergics to 2 agonist inhalations remains controversial in the treatment of children and adolescents with asthma exacerbations.To examine the efficacy of three management strategies for adding anticholinergics to 2 agonists, Plotnick and Ducharme (p 971) systematically reviewed 10 randomised controlled trials, including single dose, multiple doses (predetermined protocol), and multiple doses (flexible protocol).Only the addition of multiple doses of anticholinergics to 2 agonists in a predetermined protocol reduced the risk of hospital admission (by 30%) and improved pulmonary function tests.Eleven children would need to be treated to avoid one admission.The use of anticholinergics in mild to moderate asthma is not supported by the available evidence.The number and size of pooled studies remain small, thus the conclusions are subject to change with future larger trials. Warm clothing and housing prevent excess winter mortalityCold weather increases death rates from heart disease, stroke, and all causes in western Europe.Donaldson et al studied mortality in Yakutsk in east Siberia, where temperatures average -26.6°C from October to March (p 978).Overall daily death rates did not rise even at temperatures of -48.2°C.An increase in deaths from respiratory disease below -20°C was balanced by a fall in deaths from injury at this temperature.The stable death rate is attributed to very warm outdoor clothing and housing as well as a reduction in outdoor trips at temperatures below -20°C.The authors suggest that most of the excess winter mortality in western Europe is preventable by personal cold protection.
Correction to: Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues
Authors: Michael Weightman, Ranjit Kini, Robert Parker, Mrigendra Das
Journal: Drugs (2022)

The article Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues, written by Michael Weightman, Ranjit Kini, Robert Parker and Mrigendra Das, was originally published electronically in SpringerLink on 28 August 2020 without open access.
Psychosocial factors influencing the eating behaviours of older adults: A systematic review
Authors: Aimee Walker-Clarke, Lukasz Walasek, Caroline Meyer
Journal: Ageing Research Reviews (2022)

Our understanding of how eating behaviours change in later life have been dominated by the studies of physiological and biological influences on malnutrition. Insights from these studies were consequently used to develop interventions, which are predominantly aimed at rectifying nutritional deficiencies, as opposed to interventions that may enable older adults to eat well and enjoy their food-related life well into older age. The objective of the present review is to summarise the existing knowledge base on psychosocial influences on eating behaviours in later life. Following comprehensive searches, review, and appraisal, 53 articles were included (22 qualitative and 31 quantitative) to provide a greater understanding of the mechanisms underpinning the psychosocial factors influencing eating behaviours. Our analysis identified eight underpinning psychosocial factors that influences eating behaviours in later life; (1) health awareness & attitudes, (2) food decision making, (3) perceived dietary control, (4) mental health & mood, (5) food emotions & enjoyment, (6) eating arrangements, (7) social facilitation, and (8) social support. The importance and lasting influence of early food experiences were also identified as contributing to eating behaviours in later life. The review concludes with the call for further investigation into specific psychosocial factors that influence eating behaviour, calls for improvements in methodologies, and a summary of psychosocial barriers and enablers to eating well in later life.
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
Authors: John A. Spertus, Mary C. Birmingham, Michael Nassif, C. V. Damaraju, Antonio Abbate, Javed Butler, David E. Lanfear, Ildiko Lingvay, Mikhail N. Kosiborod, James L. Januzzi
Journal: Nature Medicine (2022)

Abstract Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors improve symptoms in patients with heart failure and reduced ejection fraction (HFrEF) and in patients with heart failure and preserved ejection fraction (HFpEF). In the midst of the Coronavirus Disease 2019 pandemic, we sought to confirm these benefits in a new type of trial that was patient centered and conducted in a completely remote fashion. In the CHIEF-HF trial ( NCT04252287 ), 476 participants with HF, regardless of EF or diabetes status, were randomized to 100 mg of canagliflozin or placebo. Enrollment was stopped early due to shifting sponsor priorities, without unblinding. The primary outcome was change in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS) at 12 weeks. The 12-week change in KCCQ TSS was 4.3 points (95% confidence interval, 0.8–7.8; P = 0.016) higher with canagliflozin than with placebo, meeting the primary endpoint. Similar effects were observed in participants with HFpEF and in those with HFrEF and in participants with and without diabetes, demonstrating that canagliflozin significantly improves symptom burden in HF, regardless of EF or diabetes status. This randomized, double-blind trial, conducted without in-person interactions between doctor and patient, can serve as a model for future all-virtual clinical trials.
DAPT de-escalation from ticagrelor to clopidogrel 1 mo after PCI for acute MI reduced net clinical events at 1 y
Authors: Richard G. Bach
Journal: Annals of Internal Medicine (2022)

Kim CJ, Park MW, Kim MC, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398:1305-16. 34627490.
Galactorrhea in a man with normal testicular function
Authors: R. S. Hulugalle
Journal: JAMA (1978)

GALACTORRHEA in men is a rare disorder. Men with galactorrhea associated with pituitary tumors and hyperprolactinemia have been described to be clinically hypogonadal.<sup>1</sup> We report the case of a man with a prolactin-secreting pituitary tumor who had normal gonadal function. <h3>Report of a Case</h3> A 28-year-old unmarried man was admitted to the Northport (NY) Veterans Administration Hospital in April 1976 with a 6 1/2-year history of milky discharge from both nipples. He complained of occasional right-sided headaches, but denied decreased libido, impotence, or visual disturbance. The patient has had bronchial asthma for the past five years, treated intermittently with hydroxyzine hydrochloride, theophylline, and ephedrine sulfate (Marax); theophylline and guaifenesin (Quibron); iodine drops; and prednisone. He denied taking these medications in the last two weeks before admission. On physical examination, the patient was 1.9 m tall and weighed 109 kg. His pulse rate was 70 beats per minute and regular;
HEPARIN
Authors: Geza de Takats
Journal: JAMA (1941)

<h3>To the Editor:—</h3> In a recent report of Ershler and Blaisdell (The Journal, September 13, p. 927) a massive hematuria was reported after the use of heparin. Heparin was administered by continuous intravenous drip for nine days. The coagulation time occasionally rose to three and four hours, but an effort was made to maintain a coagulation time of approximately one hundred and twenty minutes. Since heparin is now being widely used in various types of intravascular thromboses, such a report may deter some men from its deserved wide application. There is no evidence to show that a prolongation of the coagulation time over twenty minutes is ever necessary. Both the Canadian (Murray, G. D. W., and Best, C. H.: The Use of Heparin in Thrombosis,<i>Ann. Surg.</i><b>108</b>:173 [Aug.] 1938) and the Swedish (Crafoord, Clarence, and Jorpes, Erick: Heparin as a Prophylactic Against Thrombosis,The Journal, June 28, p.
HIV Prevalence Estimates—United States, 2006
Journal: JAMA (2009)

Accurate and timely data on the number of persons in the United States living with human immunodeficiency virus (HIV) infection (HIV prevalence) are needed to guide planning for disease prevention, program evaluation, and resource allocation. However, overall HIV prevalence cannot be measured directly because a proportion of persons infected with HIV have neither been diagnosed nor reported to local surveillance programs. In addition, national HIV prevalence data are incomplete because local reporting systems for confidential, name-based HIV reporting have been fully implemented only since April 2008. With the advent of highly active antiretroviral therapies that delay the progression of HIV to acquired immunodeficiency syndrome (AIDS), and of AIDS to death, and changes in the AIDS case definition to include an immunologic diagnosis, earlier back-calculation methods from the 1990s for estimating HIV prevalence based on the number of reported AIDS cases are no longer reliable. With 80% of states reporting name-based HIV diagnoses as of January 2006, an extended back-calculation method now can be used to estimate HIV prevalence more accurately. Based on this method, CDC now estimates that 1.1 million adults and adolescents (prevalence rate: 447.8 per 100,000 population) were living with diagnosed or undiagnosed HIV infection in the United States at the end of 2006. The majority of those living with HIV were nonwhite (65.4%), and nearly half (48.1%) were men who have sex with men (MSM). The HIV prevalence rates for blacks (1,715.1 per 100,000) and Hispanics (585.3 per 100,000) were, respectively, 7.6 and 2.6 times the rate for whites (224.3 per 100,000).
Use of Intravesical Chemotherapy in the US Following Publication of a Randomized Clinical Trial
Authors: Patrick Lewicki, Spyridon P. Basourakos, Camilo Arenas-Gallo, Yuqing Qiu, Megan Prunty, Douglas S. Scherr, Jonathan E. Shoag
Journal: JAMA Network Open (2022)

This cross-sectional study examines the use of intravesical chemotherapy after transurethral resection of bladder tumor before and after publication of a randomized clinical trial showing the benefits of intravesical chemotherapy.
BBS volume 1 issue 3 Front matter
Authors: Irving Kupfermann, Klaudiusz Weiss, G Hoyle, J Andreae, P Balaban, M Bennett, T Bullock, R Burke, D Chappie, W Davis, W Evoy, J Fentress, C Fowler, M Turvey, P Fraser, S Grillner, A Herman, G Horridge, J Lies, S Kater, B Granzow, F Krasne, W Kristan, J Weeks, J Larimer, E Lewis, R Llinasand, M Bunge, J Lynch, } Mccarthy, D Rosenbaum, P Stein, Y Tsukada, C Wiersma, J Wine, R Zucker, Dalbir Bindra, With Commentary, M Bitterman, A Black, R Bolles, D Booth, A Catania, D Dennett, R Epstein, J Flynn, C Gallistel, R Gilbert, E Hilgard, S Hulse, F Irwin, H Jenkins, H Kendler, P Killeen, M Klingsporn, F Logan, N Mackintosh, J Mazur, E Menzel, O Mowrer, E Murray, D Navarick, J Notterman, K Pribram, J Rosenblatt, T Ryan, K Salzinger, S Soltysik, A Staats, D Stein, R Teevan, E Von Glasersfeld, J Warren, E Wasserman, R Wong, W Wood, Zenon Pylyshyn, M Arbib, M Atherton, L Cohen, S Cushingand, N Hornstein, Z Domotor, H Dreyfus, H Goodluck, L Harmon, J Haugeland, Pvj Hayes, P John Son-Laird, K Leibovic, D Lenat, C Longuet-Higgins, J Mcdermott, A Newell, A Ortony, J Pascual-Leone, R Rodger, R Schank, T Simon, A Sloman, N Sutherland, M Treisman, S Ullman, W Weimer, Y Wilks, P Roland, W Chappie, J Dickinson, J Duysens, G Loeb, P Dyhre-Poulsen, H.-J Freund, G Goodwin, R Granit, P Grigg, A Iannone, J Kelso, M Levitt, B Libet, D Mccloskey, J Millar, G Mpitsos, L Pubols, T Roberts, W Shebilske, G Somjen, K.-H Sontag, J Stein, J Stevens, C Trevarthen, E Walsh, M Wells, M Wiesendanger
Journal: Behavioral and Brain Sciences (1978)

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.